Prahlad Singh, PerkinElmer CEO
July 26, 2021 10:15 AM EDTUpdated July 30, 02:31 PM
Deals
Outsourcing

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

Max Gelman

Senior Editor

PerkinElmer has been busy on the ac­qui­si­tion front through­out the Covid-19 pan­dem­ic, and on Mon­day, the Mass­a­chu­setts-based di­ag­nos­tics and life sci­ences com­pa­ny added the biggest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times